All News

Tafenoquine’s approval was the culmination of years of scientific discovery and research by experts in the field of Malariology and Infectious Disease, involving over 25 clinical trials and over 3000 participants.

A team of researchers from Columbia University, New York City compared the incidence of chlamydia infection in adolescent LARC users to non-LARC users.

The 48-week phase 4 study showed that tocilizumab was more effective than rituximab in patients with rheumatoid arthritis with low B cell levels in synovial tissue.

The Clinical Performance and Quality Measures included 6 performance measures, 6 process quality measures, and a new category of 10 structural quality measures for adults with high blood pressure.

Top news of the day from across the health care landscape.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the benefits of attending NASP during the NASP Annual Meeting in Washington, DC.

Certain subgroups may see a greater reduction in heart failure hospitalizations and cardiovascular death with the combination of sacubitril and valsartan.

The FDA has granted approvel to Alnylam’s givosiran (Givlaari) for the treatment of adults with acute hepatic porphyria.

Durvalumab (Imfinzi, AstraZeneca) and tremelimumab plus chemotherapy improved progression-free survival in first-line stage 4 non-small cell lung cancer.

Top news of the day from across the health care landscape.

The Community Pharmacy Foundation recently sponsored a study entitled, “Evaluation Of Enhanced Community Pharmacy Services.”

A recent study suggests that hyperkalemia and uncomplicated hyperglycemia in patients treated in the emergency department is commonly caused by iatrogenesis.

FDA draft guidance allows for an animal drug to be compounded from bulk drug substances in limited circumstances for which there is no FDA-approved treatment.

Officials from the FDA have approved MiSight 1-day contact lenses (CooperVision), a daily wear, single use contact lens indicated for the use of myopia management. This is the first FDA-approved product clinically proven to slow the progression of myopia, or near-sightedness, when initially prescribed for children ages 8-12 years.

Clinical data has illustrated how digital interventions can have a substantial material benefit on glycemic control in users with diabetes, with 73 of 162 users in the study reducing their average blood glucose levels to under 140 mg/dL.

The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

Researchers in the JADE MONO-1 study investigated whether patients aged 12 years and older with moderate to severe atopic dermatitis would achieve with abrocitinib could achieve clear or almost clear skin with abrocitinib.

Top news of the day from across the health care landscape.

Jesse C. Dresser, Esq explains the current climate of PBM reform at the NASP Annual Meeting in Washington, DC.

Why is this woman in opioid withdrawal despite high dose methadone administration?

A newly-developed machine learning system may help act as an alert system for potential adverse effects from drug-drug interactions.

Top news of the day from across the health care landscape.

An analysis presented at the American Heart Association Annual Scientific Sessions showed that evolocumab (Repatha, Amgen) lowered the risk of cardiovascular events in patients who have recently had a heart attack.

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.

Implementing more aggressive treatment plans from the American Heart Association’s 2017 guide were seen as more cost-effective over 10 years.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the goals and importance of his company, Stack, during the NASP Annual Meeting in Washington, DC.

Top news of the week from Specialty Pharmacy Times.